Stoke Therapeutics Q3 EPS $(1.08) Misses $(0.93) Estimate, Sales $11.255M Beat $8.185M Estimate
Benzinga Newsdesk 2 days ago
NewsEarningsEarnings BeatsEarnings Misses
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.13 percent. This is a 66.15 percent decrease over losses of $(0.65) per share
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.13 percent. This is a 66.15 percent decrease over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $11.255 million which beat the analyst consensus estimate of $8.185 million by 37.51 percent. This is a 5.86 percent increase over sales of $10.632 million the same period last year.